Aptamer Group Share News (APTA)

Aptamer Group Information

Share Price Information for Aptamer Group (APTA)

Share Price is delayed by 15 minutes

Get Live Data

0.525 0.025 (4.76%)

Bid:

0.50

Ask:

0.55

Spread: 0.05 (10.00%)

Market Cap: £19.00m

Last checked at -

Intraday Aptamer Group Share Chart

REMOVE ADS

Aptamer says new Optimer+ delivers improved results

Tue, 27th Feb 2024 14:27

(Alliance News) - Aptamer Group PLC on Tuesday said its new Optimer+ platform delivers improved results compared to standard binders.

The York, England-based biotechnology firm said its updated Optimer+ platform can produce highly specific binders with significantly higher affinity than the current technology platform. Development times for Optimer+ are also significantly faster than existing Aptamer-based approaches, it added.

Aptamer also noted that lab-based results showed that Optimer+ binders appear stable in blood serum and are not harmful to cells. Additionally, it said preliminary experiments in mice have shown Optimer+ binders to be well tolerated.

Chief Technical Officer Arron Tolley said: "Since we received the proceeds of the September fundraise, the team has worked hard to accelerate the development of Optimer+ and to show the new platform's capabilities. The development of this platform is integral to our mission to stay at the forefront of binder technologies. Both the lab-based research and the initial animal experiments suggest that Optimer+ will be well placed to deliver the next generation of binders to enable the targeted delivery of precision medicines. This is an area where we are seeing increasing interest due to the unmet needs across gene therapy and precision chemotherapy."

Shares in Aptamer were up 4.5% at 0.86 pence each in London on Tuesday afternoon.

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com